Alert detail
FDA Approval: BESREMI (ROPEGINTERFERON ALFA-2B) — Type 1 - New Molecular Entity
Policy ID: FDA-BLA761166Specialty: HematologyAdded: 7/1/2026Effective: 2021-11-12billing update
Full alert analysis requires a subscription
Subscribe to access the complete alert summary, AI-generated action recommendations, source document links, LCD revision comparisons, and related alerts.